Clinical trials: Circulatory Disorders
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Fabry Disease
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00074984
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 82 people
- Sponsor
- Genzyme, a Sanofi Company
Hypertension
The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)
This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.
- Trial name
- NCT00943852
- Testing
- losartan potassium, Comparator: isosorbide mononitrate (ISMN), Comparator: losartan + ISMN
- Volunteers
- 13 people
- Sponsor
- Organon and Co
Venous Thromboembolism
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
Trauma patients are at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of DVT varies greatly from 5-63% among studies depending on patient's individual risk factors, modality of…
- Trial name
- NCT00531843
- Testing
- fondaparinux sodium, sequential compression devices
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mary Knudson, M.D.
Peripheral Arterial Disease
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits.
- Trial name
- NCT00687076
- Testing
- Ezetimibe, Niaspan, Statin therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Baylor College of Medicine
Metabolic Syndrome
Canadian Health Advanced By Nutrition and Graded Exercise
The overall objective of the CHANGE initiative is to change the delivery of care in primary care clinics to treat disease by reducing reliance on drugs and hospitals through the promotion of scientifically validated nutritional…
- Trial name
- CHANGE (NCT01616563)
- Testing
- Dietary Intervention, Exercise Prescription and Fitness Program
- Where
- 3 sites in Canada
- Volunteers
- 305 people
- Sponsor
- Daren K. Heyland
Aging
CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy
The purpose of this study is to test the hypothesis that two years of sustained 25% caloric restriction (CR) in men age 21-50 (inclusive) and women age 21-47 (inclusive) will slow aging and protect against age-related disease…
- Trial name
- NCT00427193
- Testing
- Caloric Restriction (CR), Control
- Where
- 3 sites in United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Duke University
Heart Failure
Patient-Reported Outcome Measurement in Heart Failure Clinic
This is a randomized study evaluating the effect of routinely collecting a standardized questionnaire of heart failure health status during heart failure clinic visits.
- Trial name
- PRO-HF (NCT04164004)
- Testing
- Kansas City Cardiomyopathy Questionnaire-12
- Where
- United States
- Volunteers
- 1,249 people
- Sponsor
- Stanford University
Cardiovascular Disease, HIV
Statin Therapy to Improve Atherosclerosis in HIV Patients
In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function.
- Conditions
- Cardiovascular Disease, HIV, Atherosclerosis, Inflammation
- Trial name
- NCT00965185
- Testing
- atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Hodgkin Disease
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy.
- Conditions
- Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
- Trial name
- NCT04459416
- Testing
- Acupuncture, opioid, Assessments
- Where
- 2 sites in United States
- Volunteers
- 299 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).
- Trial name
- NCT04700176
- Testing
- Daratumumab, Pomalidomide, All-trans retinoic acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hackensack Meridian Health
Hypertension
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging design intended for conduct as a multicenter trial.
- Trial name
- NCT00244621
- Testing
- candesartan cilexetil (Atacand)
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Refractory Multiple Myeloma
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Pomalidomide and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT01212952
- Testing
- pomalidomide, bortezomib, dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Cerebral Infarction
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction.
- Trial name
- NCT00684515
- Testing
- Vorapaxar 2.5 mg, Vorapaxar 1 mg, Aspirin 75-150 mg
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Hypertension, Diastolic Dysfunction
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7…
- Trial name
- NCT00523549
- Testing
- valsartan, amlodipine
- Where
- United States
- Volunteers
- 229 people
- Sponsor
- Novartis Pharmaceuticals
Stroke
Non-invasive Brain Stimulation (NIBS) and Dual-task Walking After Stroke
The study aims to identify neural locus critical for dual-task walking (walking and talking) in individuals with stroke. To achieve this aim, the investigators apply repetitive transcranial magnetic stimulation (rTMS) to…
- Trial name
- NCT03442868
- Testing
- high frequency rTMS
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Texas Woman's University
Waldenstrom's Macroglobulinemia
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM.
- Trial name
- NCT00492050
- Testing
- Bortezomib, Rituximab, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Sudden Cardiac Death
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of…
- Trial name
- APPRAISE ATP (NCT02923726)
- Testing
- Arm 1 (ATP+Shock), Arm 2 (shock only)
- Where
- 134 sites in United States, Austria and 6 more
- Volunteers
- 2,692 people
- Sponsor
- Boston Scientific Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.